Is Tarceva a subsidiary of Roche?

Tarceva is not a subsidiary but a branded drug marketed by Roche through its pharmaceuticals division. Roche holds international marketing rights, while its subsidiary Genentech holds U.S. rights. The drug was originally developed by OSI Pharmaceuticals, which was acquired by Astellas Pharma in 2010, but Roche and Genentech retained their marketing rights to Tarceva.

Is Tarceva publicly traded?

Tarceva itself is not publicly traded. Parent company Roche Holding AG is publicly traded on the SIX Swiss Exchange (ROG) and available on U.S. OTC markets (RHHBY). Roche reported total revenue of approximately 60.9 billion Swiss francs in 2024. The founding Hoffmann and Oeri-Hoffmann families maintain voting control through a dual-share structure.

When was Tarceva approved?

The FDA approved Tarceva in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In 2005, the FDA expanded approval to include use in combination with gemcitabine for pancreatic cancer. In 2010, Tarceva was approved as first-line maintenance therapy for EGFR mutation-positive lung cancer.

What is Tarceva used for?

Tarceva (erlotinib) is used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It is an EGFR tyrosine kinase inhibitor that blocks the signaling pathway cancer cells use to grow. For lung cancer, it is most effective in patients with specific EGFR mutations. For pancreatic cancer, it is used in combination with gemcitabine chemotherapy.

Is generic erlotinib available?

Yes, generic erlotinib is widely available. Multiple manufacturers have received FDA approval for generic erlotinib, including Teva Pharmaceutical Industries, Mylan (Viatris), and various Indian pharmaceutical companies. Generic versions cost a fraction of the branded Tarceva price, significantly improving patient access to the treatment.

What are the side effects of Tarceva?

Common side effects of Tarceva include rash, diarrhea, fatigue, and loss of appetite. Serious side effects include interstitial lung disease (approximately 1-2% of patients), severe skin reactions including Stevens-Johnson syndrome, liver damage, and gastrointestinal perforations. The drug carries FDA boxed warnings for these serious risks.

Healthcare & Pharmaceuticals

Who Owns Tarceva?

Tarceva is owned by Roche Holding AG (SIX: ROG / OTCQX: RHHBY), a publicly traded Swiss multinational healthcare company headquartered in Basel, Switzerland. Roche markets Tarceva (generic name erlotinib) through its pharmaceuticals division. The drug is an EGFR tyrosine kinase inhibitor used to treat non-small cell lung cancer and pancreatic cancer. Generic versions are now widely available following patent expiration.

Parent Company

Roche

Founded

2004

Status

Publicly Traded

Headquarters

Basel, Switzerland

Tarceva Timeline

1896

Roche

Parent company established in Basel, Switzerland

Company Founded

2004

Tarceva

Founded by Genentech, OSI Pharmaceuticals

Founded

highestablishedGlobalunisexOfficial Website

Who Owns Tarceva?

Parent Company: Roche
Ownership Type: Wholly owned
Company Type: Publicly Traded
Stock Ticker: SIX: ROG

Brand	Parent Company	Ownership Type
Tarceva	Roche	Wholly owned

Where to Buy

Disclosure: We may earn commission from purchases

Tarceva on Amazon

History of Tarceva

Founded: 2004
Founders: Genentech, OSI Pharmaceuticals

Tarceva (erlotinib) was developed in the late 1990s by OSI Pharmaceuticals, a biotechnology company based in Melville, New York. OSI scientists identified erlotinib as a small molecule inhibitor of the epidermal growth factor receptor (EGFR), a protein that is overexpressed in many cancers. The drug works by blocking the signaling pathway that cancer cells use to grow and divide.

The development of Tarceva was a collaborative effort. OSI discovered the molecule, while Genentech (acquired by Roche in 2009 for $46.8 billion) contributed clinical development expertise and held U.S. commercialization rights. Roche held international commercialization rights outside the United States.

The FDA approved Tarceva in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. The approval was based on a clinical trial showing that Tarceva improved overall survival compared to placebo in patients with advanced lung cancer. This was a significant milestone, as Tarceva was one of the first targeted therapies for lung cancer.

In 2005, the FDA expanded Tarceva's approval to include use in combination with gemcitabine for first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer, and Tarceva provided a modest but statistically significant survival benefit when combined with gemcitabine.

In 2010, the FDA further approved Tarceva as a first-line maintenance therapy for EGFR mutation-positive non-small cell lung cancer. This approval was based on clinical trials showing that patients with specific EGFR mutations responded particularly well to Tarceva, establishing the importance of biomarker testing in lung cancer treatment.

The 2010s brought challenges for Tarceva. Newer targeted therapies, particularly osimertinib (Tagrisso, also marketed by AstraZeneca) and other third-generation EGFR inhibitors, demonstrated superior efficacy compared to first-generation drugs like Tarceva. These newer drugs became preferred first-line treatments for EGFR-mutant lung cancer, reducing Tarceva's clinical use.

Tarceva's patents began expiring in the late 2010s and early 2020s. Generic erlotinib entered the market in many countries, significantly reducing the brand's revenue. In the United States, multiple generic manufacturers received FDA approval for erlotinib, leading to substantial price reductions. As of 2026, Tarceva is primarily used in specific clinical scenarios where newer therapies are not available or appropriate, and generic erlotinib dominates the market.

About Roche

Roche operates through two main business divisions: Pharmaceuticals and Diagnostics, creating a unique integrated healthcare company that combines treatment and diagnostic capabilities. This dual focus enables Roche to deliver personalized healthcare solutions, matching patients with the most effective treatments based on diagnostic information and molecular characteristics.

The Pharmaceuticals division develops and manufactures prescription medicines across multiple therapeutic areas, with particular strength in oncology, immunology, neuroscience, infectious diseases, and rare diseases. Roche's pharmaceutical portfolio includes both established blockbuster products and innovative new treatments that address significant unmet medical needs. The division maintains a global research and development network with facilities across multiple continents, investing billions annually in pharmaceutical innovation, clinical trials, and regulatory approvals.

The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices that support healthcare professionals in disease detection, monitoring, and treatment selection. Roche's diagnostic capabilities include automated laboratory systems, molecular testing platforms, and digital health solutions. The division's integrated approach with pharmaceuticals creates unique advantages in personalized medicine, enabling precise treatment selection based on diagnostic information.

Roche's business philosophy emphasizes innovation, patient-centricity, and sustainable value creation. The company maintains a strong focus on research and development, with approximately 20% of pharmaceutical revenues invested in R&D activities. This investment supports a robust pipeline of new treatments and diagnostic solutions, with 10 key molecules advancing into phase III development in 2025 alone.

Financial performance in 2025 demonstrated the strength of Roche's integrated business model. The company reported 7% sales growth at constant exchange rates to CHF 61.5 billion, with the Pharmaceuticals Division achieving 9% growth and the Diagnostics Division growing 2%. Core operating profit increased by 13%, reflecting operational efficiency and strong demand for both pharmaceutical and diagnostic solutions.

Key growth drivers in 2025 included Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. These products demonstrate Roche's strength across multiple therapeutic areas and its ability to deliver innovative treatments that address significant patient needs.

Looking toward 2026, Roche expects Group sales growth in the mid single digit range and core earnings per share growth in the high single digit range at constant exchange rates. The company plans to further increase its dividend to CHF 9.80 per share, which would mark the 39th consecutive dividend increase if approved by shareholders. For 2026, Roche is shifting focus from consolidation to optimization, emphasizing internal pipeline development and R&D process improvements to enhance productivity and decision-making.

Roche's strategic priorities include investing in programs with potential to redefine care standards, particularly in oncology, neuroscience, and immunology. The company maintains a $10 billion annual budget for potential acquisitions and partnerships, prioritizing strategic fit and scientific differentiation over transaction size. This approach reflects Roche's commitment to long-term value creation and sustainable growth while maintaining operational discipline.

Founded: 1896
Headquarters: Basel, Switzerland
Company Type: Publicly Traded
Stock: SIX: ROG
Revenue: CHF 61.5 billion (FY2025)
Employees: Approximately 101,000

Visit Roche website

View full company profile for Roche

Where Is Tarceva Made / Based?

Headquarters: Basel, Switzerland
Manufacturing / Operations: Switzerland, United States

Tarceva Categories & Tags

Oncology Lung Cancer Pancreatic Cancer Prescription Drug Egfr Inhibitor

Tarceva Sustainability & Ethics

Roche publishes comprehensive sustainability reports covering its environmental impact, access to healthcare initiatives, and ethical business practices. The company has committed to becoming carbon neutral in its own operations by 2050 and has set intermediate targets for reducing greenhouse gas emissions, water consumption, and waste generation.

A key ethical issue for Tarceva and other oncology drugs is access and affordability. When Tarceva was first launched, its high price (approximately $4,000-$5,000 per month in the United States) made it inaccessible to many patients, particularly in developing countries. Roche has implemented patient access programs in some markets, but the cost of targeted cancer therapies remains a significant global health equity concern.

With the availability of generic erlotinib, access has improved substantially. Generic versions cost a fraction of the branded price, making the treatment available to far more patients globally. However, newer EGFR inhibitors that have replaced Tarceva clinically remain expensive, perpetuating the access challenge.

Roche has also faced scrutiny over its clinical trial practices, particularly regarding the transparency of trial results and the inclusion of diverse patient populations. The company has committed to publishing trial results and has improved diversity in its clinical trials, though critics argue that more progress is needed.

Tarceva Recalls & Controversies

Tarceva has been associated with several safety concerns and regulatory actions throughout its market history.

Serious Side Effects: Tarceva carries boxed warnings for several serious adverse effects. Interstitial lung disease (ILD), a potentially fatal lung condition, has been reported in patients taking Tarceva. The incidence is approximately 1-2% of patients, but the condition can be life-threatening. Other serious side effects include severe skin reactions (including Stevens-Johnson syndrome), liver damage, and gastrointestinal perforations. The FDA required warnings about these risks on the drug's label.

Patent Litigation: Tarceva was the subject of significant patent litigation. In 2016, the U.S. Supreme Court ruled in Teva Pharmaceuticals USA v. Sandoz that appellate courts must review district court claim construction rulings under the clearly erroneous standard. This case involved Tarceva's patent and had broader implications for patent law. Additionally, OSI Pharmaceuticals and Roche engaged in multiple patent disputes with generic manufacturers seeking to launch erlotinib.

Pricing Criticism: Tarceva's high price drew criticism from patient advocacy groups and policymakers. At its peak, the drug cost approximately $4,000-$5,000 per month in the United States, placing significant financial burden on patients and healthcare systems. Critics argued that the pricing was disproportionate to the modest survival benefits the drug provided, particularly in pancreatic cancer where the survival advantage was measured in weeks.

Marketing Practices: Like many pharmaceutical companies, Roche has faced scrutiny over its marketing practices for oncology drugs. The company has been investigated by regulatory authorities in several countries regarding promotional activities and the accuracy of efficacy claims. While no major enforcement actions specifically targeting Tarceva have been publicized, the broader pharmaceutical industry's marketing practices remain under ongoing regulatory scrutiny.

Tarceva Ownership: Pros & Cons

Advantages

+Backed by Roche's extensive oncology research and development infrastructure
+Established clinical track record with FDA approvals for lung and pancreatic cancer
+Generic versions now widely available, improving patient access
+Important treatment option in markets where newer therapies are not available
+Well-understood safety and efficacy profile from years of clinical use

Considerations

-Largely superseded by newer-generation EGFR inhibitors in clinical practice
-Serious side effects including interstitial lung disease and severe skin reactions
-High original branded price created access barriers for many patients
-Generic competition has significantly reduced branded revenue
-Modest survival benefits, particularly in pancreatic cancer

Frequently Asked Questions About Tarceva

Sources & Further Reading

Competitors to Tarceva

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
Adcetris	Pfizer	United States	2011	Mass market	North america	All Genders
Afinitor	Novartis	Switzerland	2009	Mass market	North america	All Genders
Tasigna	Novartis	Switzerland	2007	Established	Global	Unisex
Taxotere	Sanofi	France	1996	Established	Global	Unisex